Loading
A phase 2 trial of CAR-T-19 cell injection in acute lymphoblastic leukaemia, run by Beijing Yongtai Ruike Biotechnology Company Ltd, now recruiting.
CAR-T-19 Injection in the Treatment of CD19-positive Relapsed/Refractory B-ALL is a phase 2 interventional study registered as NCT06179524 by Beijing Yongtai Ruike Biotechnology Company Ltd, with 100 participants planned, started 2024-01-03 and due to reach its primary completion in 2025-06-30. Interventions recorded: CAR-T-19 cell injection.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Acute lymphoblastic leukaemia and the tag pipeline.
Shares Acute lymphoblastic leukaemia and the tag pipeline.
Shares Acute lymphoblastic leukaemia and the tag pipeline.
Shares CD19 and the tag pipeline.
Shares CD19, Acute lymphoblastic leukaemia and the tag pipeline.
Shares CD19, Acute lymphoblastic leukaemia and the tag pipeline.
Shares CD19, Acute lymphoblastic leukaemia and the tag pipeline.
Shares CD19 and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/